Details of Disease

General Information of Disease (ID: DISGSZ65)

• Disease Name: Bone resorption
• Disease Class: FC0Z: Musculoskeletal system/connective tissue disease
• Definition: A disease that has its basis in the disruption of bone resorption. Bone resorption is a process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products.
• Disease Hierarchy:
  DIS90YV3: Bone remodeling disease
  DISGSZ65: Bone resorption
• ICD Code:
  ICD-11: ICD-11: FC0Z
  ICD-10: ICD-10: M80
• Disease Identifiers:
  MONDO ID: MONDO_0000837
  MESH ID: D001862
  UMLS CUI: C0005974
  MedGen ID: 14188
  SNOMED CT ID: 22200009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
OLPADRONIC ACID SODIUM SALT	DM1XJBE	Investigative	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AHR	TT037IE	Definitive	Biomarker	[2]
BMP7	TTKOBRA	Definitive	Therapeutic	[3]
CXCL2	TTZF0K2	Definitive	Therapeutic	[4]
CYP19A1	TTSZLWK	Definitive	Biomarker	[5]
GHRL	TT1OCL0	Definitive	Therapeutic	[6]
PTH	TT6F7GZ	Definitive	Biomarker	[7]
TNFRSF11B	TT2CJ75	Definitive	Biomarker	[8]
TNFSF11	TT9E8HR	Definitive	Biomarker	[9]

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
COL2A1	OT5E59C8	Definitive	Biomarker	[10]
PTHLH	OTI1JF13	Definitive	Biomarker	[11]

References

• [1] Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4.
• [2] Transgenic mice with a constitutively active aryl hydrocarbon receptor display a gender-specific bone phenotype.Toxicol Sci. 2010 Mar;114(1):48-58. doi: 10.1093/toxsci/kfp284. Epub 2009 Nov 24.
• [3] Bisphosphonate rescue in distraction osteogenesis: a case series.J Pediatr Orthop. 2007 Jun;27(4):467-71. doi: 10.1097/01.bpb.0000271326.41363.d1.
• [4] CXCL2 mediates lipopolysaccharide-induced osteoclastogenesis in RANKL-primed precursors.Cytokine. 2011 Jul;55(1):48-55. doi: 10.1016/j.cyto.2011.03.026. Epub 2011 Apr 20.
• [5] Dietary bisphenol A prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19 ).Eur J Biochem. 2002 Apr;269(8):2214-22. doi: 10.1046/j.1432-1033.2002.02879.x.
• [6] Ghrelin protects against depleted uranium-induced bone damage by increasing osteoprotegerin/RANKL ratio.Toxicol Appl Pharmacol. 2018 Mar 15;343:62-70. doi: 10.1016/j.taap.2018.02.015. Epub 2018 Feb 22.
• [7] The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan.Biol Pharm Bull. 1998 Dec;21(12):1322-6. doi: 10.1248/bpb.21.1322.
• [8] RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-B activation and down regulating inflammatory cytokines.Chem Biol Interact. 2013 Apr 25;203(2):467-79. doi: 10.1016/j.cbi.2012.12.016. Epub 2013 Jan 17.
• [9] Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation.Biochim Biophys Acta. 2015 Nov;1852(11):2432-41. doi: 10.1016/j.bbadis.2015.08.018. Epub 2015 Aug 28.
• [10] Yohimbine hydrochloride ameliorates collagen type-II-induced arthritis targeting oxidative stress and inflammatory cytokines in Wistar rats.Environ Toxicol. 2017 Feb;32(2):619-629. doi: 10.1002/tox.22264. Epub 2016 Mar 29.
• [11] Osteoclasts play a part in pain due to the inflammation adjacent to bone.Bone. 2006 Nov;39(5):1107-1115. doi: 10.1016/j.bone.2006.04.033.